Pelthos Therapeutics Inc Dossier - Source-backed chat

Pelthos Therapeutics Inc

PTHSNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.36

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $20.35Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $77.9M

Enterprise Value $97M

Shares Outstanding 3.8M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pelthos Therapeutics (NYSE American: PTHS) represents a compelling specialty dermatology commercialization play. Formed via a 2025 merger backed by Ligand Pharmaceuticals, the company has successfully transitioned into a commercial-stage entity. Its flagship product, ZELSUVMI, is the first and only FDA-approved at-home prescription treatment for molluscum contagiosum, addressing a massive pediatric and adult market. Recent Q1 2026 results demonstrate strong commercial execution with a 17% quarter-over-quarter revenue increase to $10.91 million and a 25% surge in prescription units. While the company is currently unprofitable and experiencing high cash burn typical of early-stage launches, its working capital has strengthened to $44.8 million. Strategic acquisitions of XEPI (for impetigo) and XEGLYZE (for head lice) provide immediate commercial synergy, leveraging the newly expanded sales force. Furthermore, significant open-market insider buying by Director Todd C. Davis (CEO of Ligand) in June 2026 signals strong institutional confidence in the stock's undervaluation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$48.00

Mean target$57.71

High · most bullish analyst$75.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial adoption of ZELSUVMI slows due to reimbursement hurdles or intense competition from office-administered therapies like Ycanth. The integration and launches of XEPI and XEGLYZE stall, leading to higher-than-expected SG&A expenses without corresponding revenue offsets. High cash burn quickly depletes the $44.8 million working capital buffer, forcing highly dilutive equity raises under the $200 million shelf registration in a high-interest-rate environment.

Base CaseCentral scenario

ZELSUVMI continues its robust upward trajectory in prescription volume, supported by expanding insurance coverage and high pediatric dermatology demand. The commercial launches of XEPI and XEGLYZE in late 2026 proceed smoothly, leveraging the existing sales infrastructure to drive immediate cross-selling synergies. The company successfully manages its cash burn, utilizing its $50 million term loan facility and achieving commercial milestones to unlock additional capital. Revenue grows steadily toward a $60M+ annualized run rate by late 2027, narrowing net losses significantly.

Bull CaseUpside scenario

Rapid commercial uptake of ZELSUVMI™ combined with successful relaunches of Xepi® and Xeglyze® leverages existing sales infrastructure to drive the company to profitability by late 2026/2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class, FDA-approved flagship product (ZELSUVMI) with exclusive at-home administration convenience for a highly contagious skin condition affecting millions.
Synergistic commercial portfolio enhanced by the strategic acquisitions of XEPI and XEGLYZE, maximizing the efficiency of the expanded dermatology sales force.
Strong strategic backing and alignment with Ligand Pharmaceuticals, highlighted by substantial indirect holdings (1.5M shares) and recent $1M open-market insider purchases by Director Todd C. Davis.
Strengthened balance sheet with $44.8 million in working capital and access to a $50 million senior secured term loan facility to fund commercial rollouts.

Key Investment Risks

High cash burn rate typical of early-stage commercial launches, which could necessitate dilutive capital raises if sales growth lags.
Reimbursement and payer coverage risks that could restrict patient access or slow down the commercial adoption of ZELSUVMI.
Pipeline development dependency on Ligand, as further development of key NITRICIL assets (SB204, SB208, SB414) requires separate licensing agreements.

Thesis Invalidation Triggers

A flatlining or sequential decline in ZELSUVMI prescription units over two consecutive quarters.
Failure to launch XEPI or XEGLYZE within the projected 2026 timelines.
Depletion of working capital below $15 million without securing non-dilutive financing or achieving positive cash flow.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.